For Oncology Nurses: Oral Selective Estrogen Receptor Degraders in Breast Cancer — Proceedings from the 2026 Annual ONS Congress

Oncology Today with Dr Neil Love · Aug 18, 2026 · 1:24:47

Listen in the Podli app 🎧

Follow your favourite podcasts, listen offline and in the car with CarPlay and Android Auto, and always pick up where you left off. Free to try.

Featuring perspectives from Ms Blanca Ledezma, Dr Marissa Marti-Smith, Dr Heather McArthur and Dr Ruth M O'Regan, moderated by Dr McArthur, including the following topics:

Introduction (0:00)
Current Clinical Role of Oral Selective Estrogen Receptor Degraders (SERDs) in HR-Positive Metastatic Breast Cancer (3:37)
Practical Considerations with Oral SERDs (15:42)
Potential Role of Combination Approaches with Oral SERDs (26:31)
Gastrointestinal Adverse Events Documented with Oral SERDs (38:17)
Potential Role of Early Therapeutic Switching After Detection of an Emergent ESR1 Mutation (46:51)
Other Class-Effect Toxicities Associated with Oral SERDs (1:00:53)
Emerging Utility of Adjuvant Oral SERDs (1:10:16)
Unique Toxicities Associated with 1 or More Oral SERDs (1:19:17)

CME information and select publications